Travel Vaccines Market by Type, Disease - Global Forecast 2024-2030

List of Tables

[192 Pages Report] The Travel Vaccines Market size was estimated at USD 8.26 billion in 2023 and expected to reach USD 9.09 billion in 2024, at a CAGR 10.06% to reach USD 16.18 billion by 2030.

The travel vaccines market encompasses the production, distribution, and administration of immunizations recommended or required for international travelers based on specific regional disease risk exposures. The ongoing growth in the travel vaccines market is primarily driven by increased international travel, rising awareness about vaccine-preventable diseases, and governmental travel regulations mandating certain vaccines for entry. Additionally, the expansion of the global tourism industry and proactive health measures by international travelers fuel the demand for travel vaccines. Technological advancements in vaccine storage and stability contribute to market growth by enabling wider vaccine accessibility and distribution. The major challenges affecting the growth of the travel vaccines market include high costs associated with vaccine development and strict regulatory requirements leading to prolonged approval times. Additionally, the limited shelf life of vaccines, cold chain logistics requirements, and vaccine hesitancy among specific traveler demographics further impede market growth. Emerging market opportunities include developing vaccines against evolving infectious disease threats and expanding the existing travel vaccine portfolio to include neglected tropical diseases. An increase in public-private partnerships for vaccine research and development and the incorporation of digital health technologies for personalized travel health advisories and vaccine reminders represent significant prospects for industry expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 8.26 billion
Estimated Year [2024]	USD 9.09 billion
Forecast Year [2030]	USD 16.18 billion
CAGR (%)	10.06%

Type: Advancements in DNA vaccines to induce immune response

Attenuated vaccines utilize a weakened form of the germ that causes a disease. Attenuated vaccines are highly effective in eliciting strong and long-lasting immune responses. Conjugate vaccines are designed to combat bacteria with polysaccharide outer coatings. By linking antigens or toxoids from a microbe that the immune system can recognize to the polysaccharides, conjugate vaccines improve the body's immune response to the bacterium. DNA vaccines represent a cutting-edge approach by directly injecting genetically engineered DNA so cells can produce an antigen and induce an immune response. Inactive vaccines use the killed version of the germ that causes a disease and are safer than live vaccines, especially for people with weakened immune systems, but may require multiple doses to maintain immunity. Recombinant vector vaccines use a virus or a bacterium to introduce microbial DNA to body cells and are sophisticated in design and capable of inducing strong immune responses. Subunit vaccines include only the essential antigens and not all other molecules of the microbe and have a lower risk of side effects but may require adjuvants to enhance the immune response. Toxoid vaccines are used against bacteria that produce toxins in the body and are made by inactivating the toxins produced by the bacteria, which in turn induces an immune response.

Disease: Need based preference for hepatitis vaccines among travelers

DPT vaccines are primarily recommended for young children, but booster shots are advised for adults traveling to areas where diphtheria and pertussis (whooping cough) are still prevalent. Hepatitis is recommended for most travelers, especially those visiting regions with higher rates of Hepatitis A infection such as Asia, Africa, and Central and South America. Japanese encephalitis is advised for travelers staying for extended periods in endemic areas, especially in rural Asia. The meningococcal vaccine is essential for travelers to sub-Saharan Africa during the dry season and for pilgrims to the Hajj in Saudi Arabia. Rabies vaccine is recommended for travelers involved in outdoor activities in areas where rabies is a risk or for those traveling to remote locations where medical care is difficult to access. Varicella (Chickenpox) is essential for non-immune travelers, particularly young adults and healthcare professionals. Yellow fever is critical for travelers to endemic regions in Africa and South America.

Regional Insights

In the Americas, the United States and Canada represent significant markets for travel vaccines, driven by high outbound travel rates and robust healthcare infrastructure. Consumer behavior shows a high degree of awareness and preparedness for travel health, leading to a steadfast demand for vaccines against diseases such as Yellow Fever, Typhoid, and Hepatitis A and B. The European Union exhibits a robust travel vaccine market due to well-established healthcare systems and high travel frequency to regions with vaccine-preventable diseases. The EU's streamlined regulatory framework fosters a conducive environment for introducing new vaccines. The Middle East & Africa region presents a varied landscape for travel vaccines, with the Gulf Cooperation Council countries showing growing demand due to increasing travel and healthcare investments. The Asia Pacific region is witnessing rapid growth in the travel vaccine market, with China, Japan, and India leading the way for market expansion. Notably, China and India invest heavily in vaccine R&D to become self-sufficient in vaccine production. Japan's market is distinguished by high consumer awareness and advanced vaccine technology, supported by government-led immunization campaigns.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Travel Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Travel Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Travel Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, Biological E Limited, Cadila Pharmaceuticals Limited, CSL Limited, Dano Vaccines & Biologicals Private Limited, Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Indian Immunologicals Ltd., Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Attenuated Vaccines
- Conjugate Vaccines
- DNA Vaccines
- Inactive Vaccines
- Recombinant Vector Vaccines
- Subunit Vaccines
- Toxoid Vaccines

Disease
- DPT
- Hepatitis A
- Hepatitis B
- Japanese Encephalitis
- Measles and Mumps
- Meningococcal
- Rabies
- Typhoid
- Varicella
- Yellow Fever

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Travel Vaccines Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Travel Vaccines Market?

3. What are the technology trends and regulatory frameworks in the Travel Vaccines Market?

4. What is the market share of the leading vendors in the Travel Vaccines Market?

5. Which modes and strategic moves are suitable for entering the Travel Vaccines Market?

Product Code: MRR-0316851957A3

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing Popularity of International Tourism
  - 5.1.1.2. Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
  - 5.1.1.3. Recent Investments and Improvement in Cold Chain Storage Infrastructure
- 5.1.2. Restraints
  - 5.1.2.1. Limited Awareness Amongst Travelers
- 5.1.3. Opportunities
  - 5.1.3.1. Innovations in Novel Vaccine Technologies and Advancements
  - 5.1.3.2. Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
- 5.1.4. Challenges
  - 5.1.4.1. Issues Related to Vaccine Handling and Storage
5.2. Market Segmentation Analysis
- 5.2.1. Type: Advancements in DNA vaccines to induce immune response
- 5.2.2. Disease: Need based preference for hepatitis vaccines among travelers
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Travel Vaccines Market, by Type

6.1. Introduction
6.2. Attenuated Vaccines
6.3. Conjugate Vaccines
6.4. DNA Vaccines
6.5. Inactive Vaccines
6.6. Recombinant Vector Vaccines
6.7. Subunit Vaccines
6.8. Toxoid Vaccines

7. Travel Vaccines Market, by Disease

7.1. Introduction
7.2. DPT
7.3. Hepatitis A
7.4. Hepatitis B
7.5. Japanese Encephalitis
7.6. Measles and Mumps
7.7. Meningococcal
7.8. Rabies
7.9. Typhoid
7.10. Varicella
7.11. Yellow Fever

8. Americas Travel Vaccines Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Travel Vaccines Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Travel Vaccines Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
- 11.3.1. India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad
- 11.3.2. FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
- 11.3.3. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

12. Competitive Portfolio

12.1. Key Company Profiles
12.2. Key Product Portfolio